Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

A Randomized Comparison of CPX-351 and FLAG-Ida in Patients with High-Risk Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome (MDS) and MDS-Related Gene Mutations: A Subgroup Analysis of the UK NCRI AML19 Trial

Priyanka Mehta, Roderick Murphy, Saemi Park, Nalina Dronamraju, Tony Wagner, Yana Lutska, Stefan Faderl, Ian Thomas, Joanna Canham, Alex Legg

Blood (2024) 144 (Supplement 1): 55.

https://doi.org/10.1182/blood-2024-207094

Published: 2024

Journal Articles

A Randomised Comparison of CPX-351 Versus Standard Daunorubicin and Cytarabine Plus Fractionated Gemtuzumab Ozogamicin in Older Adults with AML without Adverse Risk Cytogenetics: Results of the NCRI AML18 Trial

Blood (2024) 144 (Supplement 1): 59.

https://doi.org/10.1182/blood-2024-200027

Published: 2024

Journal Articles

Molecular MRD is strongly prognostic in patients with NPM1 -mutated AML receiving venetoclax-based nonintensive therapy

Blood (2024) 143 (4): 336–341.

https://doi.org/10.1182/blood.2023021579

Published: 2024

Includes: Supplemental data

Journal Articles

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial

Blood (2023) 142 (20): 1697–1707.

https://doi.org/10.1182/blood.2023020630

Published: 2023

Includes: Supplemental data

Journal Articles

MRD Directed Treatment Intensification with Either FLAG-Ida or DA-Cladribine Improves Survival in Older AML Patients: Results from the NCRI AML18 Randomised Trial

Nigel H. Russell, Abin Thomas, Robert Hills, Ian Thomas, Amanda Gilkes, Nuria Almuina, Sarah Burns, Lucy Marsh, Georgia Andrew, Nicholas McCarthy, Jennifer Byrne, Rob Sellar, Richard J. Kelly, Paul Cahalin, Ulrik Malthe Overgaard, Priyanka Mehta, Mike Dennis, Steve Knapper, Sylvie D Freeman

Blood (2023) 142 (Supplement 1): 830.

https://doi.org/10.1182/blood-2023-185956

Published: 2023

Journal Articles

Real-World Treatment Patterns and Clinical Outcomes in Newly Diagnosed Acute Myeloid Leukemia with and without mIDH1 Treated with Intensive Chemotherapy from an International Real-World Database (REAL-IDH)

Joshua F. Zeidner, Priyanka Mehta, Benyam Muluneh, Sarah Bertoli, Pierre-Yves Dumas, Arnaud Pigneux, Cédric Fernandez, Hélène Derrien, Christian Recher

Blood (2023) 142 (Supplement 1): 3816.

https://doi.org/10.1182/blood-2023-188548

Published: 2023

Journal Articles

FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial

Nigel H. Russell, Charlotte Wilhelm-Benartzi, Steve Knapper, Leona M Batten, Joanna Canham, Emily L Hinson, Ulrik Malthe Overgaard, Amanda Gilkes, Jad Othman, Nicola Potter, Richard Dillon, Priyanka Mehta, Panagiotis Kottaridis, Jamie Cavenagh, Claire Hemmaway, Claire Arnold, Sylvie D Freeman, Mike Dennis

Blood (2022) 140 (Supplement 1): 526–528.

https://doi.org/10.1182/blood-2022-162377

Published: 2022

Journal Articles

CREST-UK: CPX-351 Real-World Effectiveness and Safety Study for the Treatment of Newly Diagnosed Therapy-Related AML and AML with Myelodysplasia-Related Changes in the UK

Priyanka Mehta, Anjum Khan, Jamie Maddox, Yngvar Floisand, Richard Whitmill, Daniel Cuadras, Montse Pedros, Saemi Park, Greg Medalla, Alex Legg, Victoria Louise Campbell

Blood (2022) 140 (Supplement 1): 6152–6154.

https://doi.org/10.1182/blood-2022-159496

Published: 2022

Journal Articles

Venetoclax-Based Non-Intensive Combinations Successfully Salvage Molecular Relapse of Acute Myeloid Leukemia and Are an Important Bridge to Cellular Therapy in Relapsed/Refractory Disease - Real-World Data from a UK-Wide Programme

Blood (2022) 140 (Supplement 1): 9016–9018.

https://doi.org/10.1182/blood-2022-167097

Published: 2022

Journal Articles

A Randomized Comparison of the Fractionated Versus Single Dose Schedule of Gemtuzumab Ozogamicin at Induction with Determinants of Benefit for Older AML Patients: UK NCRI AML18 Trial Results

Blood (2022) 140 (Supplement 1): 532–533.

https://doi.org/10.1182/blood-2022-162245

Published: 2022

Journal Articles

Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial

Jad Othman, Richard Dillon, Charlotte Wilhelm-Benartzi, Steve Knapper, Leona M Batten, Joanna Canham, Emily L Hinson, William Villiers, Michelle Kleeman, Amanda Gilkes, Nicola Potter, Ulrik Malthe Overgaard, Priyanka Mehta, Panos Kottaridis, Jamie Cavenagh, Claire Hemmaway, Claire Arnold, Mike Dennis, Nigel H. Russell

Blood (2022) 140 (Supplement 1): 1036–1038.

https://doi.org/10.1182/blood-2022-159433

Published: 2022

Journal Articles

A Randomised Evaluation of Low-Dose Ara-C Plus BCT-100 Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial

Francis J. Mussai, Ian Thomas, Cono Ariti, Laura Upton, Mia Sydenham, Alan K. Burnett, Steve Knapper, Priyanka Mehta, Mary Frances McMullin, Mhairi Copland, Nigel H. Russell, Robert Hills

Blood (2021) 138 (Supplement 1): 2355.

https://doi.org/10.1182/blood-2021-148323

Published: 2021

Journal Articles

A Randomised Evaluation of Low-Dose Cytarabine Arabinoside Plus Lenalidomide Versus Single-Agent Low-Dose Cytarabine Arabinoside in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial

Mhairi Copland, Cono Ariti, Ian Thomas, Laura Upton, Mia Sydenham, Priyanka Mehta, Shahidul Islam, Lars Kjeldsen, Alan K. Burnett, Robert Hills, Nigel H. Russell, Mike Dennis

Blood (2021) 138 (Supplement 1): 1266.

https://doi.org/10.1182/blood-2021-147802

Published: 2021

Journal Articles

Low Incidence of COVID-19 Infection in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity/Venetoclax Based Treatment: Initial Results of the PACE Prospective Clinical Study from the UK Trials Acceleration Program

Blood (2021) 138 (Supplement 1): 1942.

https://doi.org/10.1182/blood-2021-146061

Published: 2021

Journal Articles

Prediction of Early Mortality with Non-Intensive Acute Myeloid Leukemia (AML) Therapies: Analysis of 1336 Patients from MRC/NCRI and SWOG

Xu Wang, Ian Thomas, Cono Ariti, Mike Dennis, Priyanka Mehta, Nigel H Russel, Mia Sydenham, Robert Hills, Alan K. Burnett, Sucha Nand, Sarit Assouline, Laura C. Michaelis, Harry P. Erba, Kathleen Kerr, Roland B. Walter, Megan Othus

Blood (2021) 138 (Supplement 1): 220.

https://doi.org/10.1182/blood-2021-151597

Published: 2021

Journal Articles

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Blood (2020) 135 (9): 680–688.

https://doi.org/10.1182/blood.2019002959

Published: 2020

Includes: Supplemental data

Journal Articles

Interim Analysis of a Prospective Multicentre Study Using Next Generation Sequencing for Kinase Domain Mutational Analysis in CML Patients on First or Subsequent TKI Therapy

Blood (2019) 134 (Supplement_1): 2935.

https://doi.org/10.1182/blood-2019-129825

Published: 2019

Journal Articles

Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3 -Internal Tandem Duplication ( FLT3 -ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial

Blood (2018) 132 (Supplement 1): 563.

https://doi.org/10.1182/blood-2018-99-110439

Published: 2018

Journal Articles

Characterisation of Histone Deacetylase (HDAC) Expression Profiles in Acute Myeloid Leukaemia: A Basis for the Development of Targeted Therapy Using Histone Deacetylase Inhibitors.

Charlotte A. Bradbury, MA, BMBch, MRCP, Farhat L. Khanim, BSc, PhD, Priyanka Mehta, MBBS, MRCP, Rachel E. Hayden, BSc, Charles F. Craddock, MRCP, MRCPath, DPhil, Chris M. Bunce, BSc, PhD, Bryan M. Turner, BSc, PhD

Blood (2004) 104 (11): 1123.

https://doi.org/10.1182/blood.V104.11.1123.1123

Published: 2004

NARROW

A Randomized Comparison of CPX-351 and FLAG-Ida in Patients with High-Risk Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome (MDS) and MDS-Related Gene Mutations: A Subgroup Analysis of the UK NCRI AML19 Trial

A Randomised Comparison of CPX-351 Versus Standard Daunorubicin and Cytarabine Plus Fractionated Gemtuzumab Ozogamicin in Older Adults with AML without Adverse Risk Cytogenetics: Results of the NCRI AML18 Trial

Molecular MRD is strongly prognostic in patients with NPM1 -mutated AML receiving venetoclax-based nonintensive therapy

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial

MRD Directed Treatment Intensification with Either FLAG-Ida or DA-Cladribine Improves Survival in Older AML Patients: Results from the NCRI AML18 Randomised Trial

Real-World Treatment Patterns and Clinical Outcomes in Newly Diagnosed Acute Myeloid Leukemia with and without mIDH1 Treated with Intensive Chemotherapy from an International Real-World Database (REAL-IDH)

FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial

CREST-UK: CPX-351 Real-World Effectiveness and Safety Study for the Treatment of Newly Diagnosed Therapy-Related AML and AML with Myelodysplasia-Related Changes in the UK

Venetoclax-Based Non-Intensive Combinations Successfully Salvage Molecular Relapse of Acute Myeloid Leukemia and Are an Important Bridge to Cellular Therapy in Relapsed/Refractory Disease - Real-World Data from a UK-Wide Programme

A Randomized Comparison of the Fractionated Versus Single Dose Schedule of Gemtuzumab Ozogamicin at Induction with Determinants of Benefit for Older AML Patients: UK NCRI AML18 Trial Results

Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial

A Randomised Evaluation of Low-Dose Ara-C Plus BCT-100 Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial

A Randomised Evaluation of Low-Dose Cytarabine Arabinoside Plus Lenalidomide Versus Single-Agent Low-Dose Cytarabine Arabinoside in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial

Low Incidence of COVID-19 Infection in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity/Venetoclax Based Treatment: Initial Results of the PACE Prospective Clinical Study from the UK Trials Acceleration Program

Prediction of Early Mortality with Non-Intensive Acute Myeloid Leukemia (AML) Therapies: Analysis of 1336 Patients from MRC/NCRI and SWOG

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Interim Analysis of a Prospective Multicentre Study Using Next Generation Sequencing for Kinase Domain Mutational Analysis in CML Patients on First or Subsequent TKI Therapy

Characterisation of Histone Deacetylase (HDAC) Expression Profiles in Acute Myeloid Leukaemia: A Basis for the Development of Targeted Therapy Using Histone Deacetylase Inhibitors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only